To Study the Individual Variants of Chemotherapy-Induced Neurotoxicity

This is a prospective, observational, cohort study, monitoring the chemotherapy-induced peripheral neurotoxicity by traditional clinical scales, neurological examinations, and semi-quantitative assessments. Moreover, all the genetic changes will be analyzed by next generation sequencing and we will try to identify relevant variants in individuals who suffer from chemotherapy-induced neurotoxicity.

Inclusion criteria

• Histologically confirmed epithelial ovarian cancer, endometrial cancer or adenocarcinoma of colon or rectum
• Pathological stage I~IV for ovarian cancer, stage II~IV endometrial cancer or stage III & high risk stage II for colorectal cancer
• Scheduled to receive adjuvant Paclitaxel/Carboplatin for ovarian or endometrial cancer, or mFOLFOX6 for colorectal cancer
• Age ≥ 20 years old
• ECOG Performance status 0-1
• Adequate organ function

Bone marrow:

Absolute neutrophil count (ANC) ≥ 1.5 x 109/L WBC ≥ 3.0 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin ≥ 9 g/dL

Hepatic:

Total bilirubin level ≤ 1.0 x UNL AST and ALT ≤ 3.0 x UNL

Renal:

Creatinine level ≤ 1.5 mg/dL in men, ≤1.4 mg/dL in women; or Estimated CCr ≥ 60 mL/min (CCr is estimated by Cockcroft-Gault formula, as appendix III).

• Negative pregnancy test for women of childbearing potential only
• Patient willing to provide blood sample for research purposes
• Written informed consent

Exclusion criteria

• Prior treatment with neurotoxic chemotherapy, such as oxaliplatin, cisplatin, carboplatin, taxanes or vinca alkaloids
• Receiving chemotherapy within 6 months
• History of allergy to 5-FU or LV
• Pre-existing peripheral neuropathy of any grade
• A family history of a genetic or familial neuropathy
• Active uncontrolled infection
• Significant medical diseases, such as unstable angina, acute or recent myocardial infarction (<6 months before enrollment), COPD with frequent exacerbation, uncontrolled hypertension, ore cent CVA (<6 months before enrollment)
• Poor compliance